Skip to main content
Rallybio Corp logo

Rallybio Corp — Investor Relations & Filings

Ticker · RLYB ISIN · US75120L1008 US Professional, scientific and technical activities
Filings indexed 245 across all filing types
Latest filing 2024-05-17 Director's Dealing
Country US United States of America
Listing US RLYB

About Rallybio Corp

https://rallybio.com/

Rallybio Corp. is a clinical-stage biotechnology company that develops and commercializes therapies for patients with severe and rare diseases. The company's development pipeline focuses on complement dysregulation and hematology. Key programs include RLYB116, a C5 inhibitor being investigated for complement-mediated diseases, and a therapy for the prevention of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT). Rallybio operates with a portfolio-based model, identifying and accelerating the development of assets such as small molecules and engineered proteins to address significant unmet medical needs.

Recent filings

Filing Released Lang Actions
FORM 4
Director's Dealing
2024-05-17 English
FORM 4
Director's Dealing
2024-05-17 English
Regulatory Filings 2024
Regulatory Filings
2024-05-16 English
Regulatory Filings 2024
Regulatory Filings
2024-05-16 English
S-3
Registration Form
2024-05-10 English
10-Q
Interim / Quarterly Report Q1 2024
2024-05-09 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.